Skip to main content

Advertisement

Table 1 Uni- and multivariate analysis for RRM2 and survival in microarray data sets

From: Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers

Data set Overall survival Progression-free survival
  HR (95% CI) Adjusted HR (95% CI)* HR (95% CI) Adjusted HR (95% CI)*
Desmedt set     
  2.27 (1.32-4.04) 2.21 (1.16-4.24) 1.75 (1.15-2.68) 2.16 (1.32-3.54)
Chin set     
  0.690 (0.37-1.29) 0.76 (0.38-1.49) 0.80 (0.41-1.54) 0.80 (0.40-1.62)
Pawitan set     
  3.10 (1.59-6.49) 2.48 (1.03-6.36) 3.65 (1.85-7.87) 3.28 (1.43-7.89)
Wang set     
  N/A N/A 2.14 (1.43-3.26) 2.20 (1.44-3.39)
Ivshina set     
  N/A N/A 2.33 (1.45-3.84) 2.21 (1.37-3.64)
NKI set     
  3.41 (2.09-5.81) 2.31 (1.38-4.02) 2.46 (1.69-3.64) 1.96 (1.31-2.98)
Pooled Analysis     
  2.09 (1.26-3.49) 2.19 (1.28-3.79) 2.32 (1.72-3.14) 2.34 (1.62-3.41)
Meta analysis#     
  2.11 (1.57-2.83) 1.78 (1.28-2.48) 2.06 (1.70-2.50) 1.99 (1.62-2.46)
  1. Note: Uni- and multivariate analysis were conducted to evaluate HR of RRM2 (high vs. low).
  2. *For multivariate analysis, HR was adjusted by age, ER status, Elston Grade in the Desmedt set; In the Chin and Ivshina data sets, HR was adjusted by age. In the Pawitan set, it was adjusted by Elston grade, ER and HER2 status. For the Wang set, HR was adjusted by ER status. The NKI set was adjusted by age and grade.
  3. #The meta analysis was conducted unsing Comprehensive Meta-Analysis V2 software with a Fixed –effect model.
  4. Statistical significance, P < 0.05; Statistical significance, P < 0.01.